Piramal Pharma Limited (NSE: PPLPHARMA)
India flag India · Delayed Price · Currency is INR
220.82
-3.29 (-1.47%)
Oct 10, 2024, 1:07 PM IST

Piramal Pharma Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Mar '24 Mar '23 Mar '22 Mar '21
Operating Revenue
83,73581,71270,81665,59158,291
Other Revenue
---1,750576.37
Revenue
83,73581,71270,81667,34158,868
Revenue Growth (YoY)
13.01%15.39%5.16%14.39%-
Cost of Revenue
33,09432,61729,71324,51220,736
Gross Profit
50,64149,09541,10342,82938,132
Selling, General & Admin
22,87522,03421,04615,88814,761
Other Operating Expenses
15,03715,05413,73615,4779,508
Operating Expenses
45,42844,49341,54937,22729,301
Operating Income
5,2144,601-446.55,6028,831
Interest Expense
-4,354-4,470-3,377-1,888-1,459
Interest & Investment Income
119.2119.216.46.837.11
Earnings From Equity Investments
675594.9543.3590.3436.06
Currency Exchange Gain (Loss)
3043041,108168.6565.57
Other Non Operating Income (Expenses)
575.7763.4523.3-94.7-50.12
EBT Excluding Unusual Items
2,5341,913-1,6334,3858,361
Merger & Restructuring Charges
---69.6-150.8-416.77
Gain (Loss) on Sale of Investments
42.742.715.819.5-
Gain (Loss) on Sale of Assets
-4.6-4.6-4.8-5.410.52
Asset Writedown
-----377.08
Other Unusual Items
-158.4-158.4490601.31,183
Pretax Income
2,4131,793-1,2024,8508,760
Income Tax Expense
2,1361,615663.11,0901,052
Net Income
277.6178.2-1,8653,7607,708
Net Income to Common
277.6178.2-1,8653,7607,708
Net Income Growth
----51.22%-
Shares Outstanding (Basic)
1,3081,2811,1901,179628
Shares Outstanding (Diluted)
1,3101,2841,1901,179628
Shares Change (YoY)
10.02%7.85%0.95%87.83%-
EPS (Basic)
0.210.14-1.573.1912.28
EPS (Diluted)
0.210.14-1.573.1912.28
EPS Growth
----74.02%-
Free Cash Flow
-2,925-4,809-1,231-42.55
Free Cash Flow Per Share
-2.28-4.04-1.04-0.07
Dividend Per Share
-0.110-0.980-
Gross Margin
60.48%60.08%58.04%63.60%64.78%
Operating Margin
6.23%5.63%-0.63%8.32%15.00%
Profit Margin
0.33%0.22%-2.63%5.58%13.09%
Free Cash Flow Margin
-3.58%-6.79%-1.83%-0.07%
EBITDA
12,14811,3915,76411,09912,970
EBITDA Margin
14.51%13.94%8.14%16.48%22.03%
D&A For EBITDA
6,9356,7906,2115,4974,139
EBIT
5,2144,601-446.55,6028,831
EBIT Margin
6.23%5.63%-0.63%8.32%15.00%
Effective Tax Rate
88.50%90.06%-22.48%12.01%
Revenue as Reported
85,30183,46673,06768,34959,806
Advertising Expenses
-1,4231,7621,513-
Source: S&P Capital IQ. Standard template. Financial Sources.